ATARA BIOTHERAPEUTICS, INC. Interest Expense
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Interest Expense of $191.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2026-06-30 was $191.00K, a 80.35% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2026-03-31 was $830.00K, a 18.39% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2025-12-31 was $894.00K, a 12.09% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2025-09-30 was $909.00K, a 23.16% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. interest expense for fiscal 2025 was $3.79M, a 17.83% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. interest expense for fiscal 2024 was $4.62M, a 12.68% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. interest expense for fiscal 2023 was $5.29M, a 1316.89% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. interest expense for fiscal 2022 was $373.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $191.00K 10-Q · filed 2026-08-12 | $1.02M 10-Q · filed 2026-08-12 | $1.92M derived: sum of 3 quarters · filed 2026-08-12 | $2.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $830.00K 10-Q · filed 2026-05-12 | $1.72M derived: sum of 2 quarters · filed 2026-05-12 | $2.63M derived: sum of 3 quarters · filed 2026-05-12 | $3.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $894.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.80M derived: sum of 2 quarters · filed 2026-03-16 | $2.77M derived: sum of 3 quarters · filed 2026-08-12 | $3.79M 10-K · filed 2026-03-16 |
| 2025-09-30 | $909.00K 10-Q · filed 2025-11-12 | $1.88M derived: sum of 2 quarters · filed 2026-08-12 | $2.90M 10-Q · filed 2025-11-12 | $3.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $972.00K 10-Q · filed 2026-08-12 | $1.99M 10-Q · filed 2026-08-12 | $3.01M derived: sum of 3 quarters · filed 2026-08-12 | $4.19M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.02M 10-Q · filed 2026-05-12 | $2.03M derived: sum of 2 quarters · filed 2026-05-12 | $3.22M derived: sum of 3 quarters · filed 2026-05-12 | $4.48M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.20M derived: sum of 2 quarters · filed 2026-03-16 | $3.46M derived: sum of 3 quarters · filed 2026-03-16 | $4.62M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.18M 10-Q · filed 2025-11-12 | $2.44M derived: sum of 2 quarters · filed 2025-11-12 | $3.60M 10-Q · filed 2025-11-12 | $4.77M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.26M 10-Q · filed 2025-08-11 | $2.42M 10-Q · filed 2025-08-11 | $3.59M derived: sum of 3 quarters · filed 2025-08-11 | $4.99M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.15M 10-Q · filed 2025-05-15 | $2.33M derived: sum of 2 quarters · filed 2025-05-15 | $3.72M derived: sum of 3 quarters · filed 2025-05-15 | $5.10M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $2.57M derived: sum of 2 quarters · filed 2025-03-07 | $3.95M derived: sum of 3 quarters · filed 2025-03-07 | $5.29M 10-K · filed 2025-03-07 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-12 | $2.77M derived: sum of 2 quarters · filed 2024-11-12 | $4.11M 10-Q · filed 2024-11-12 | $4.23M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.38M 10-Q · filed 2024-08-12 | $2.71M 10-Q · filed 2024-08-12 | $2.83M derived: sum of 3 quarters · filed 2024-08-12 | $2.95M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.34M 10-Q · filed 2024-05-09 | $1.45M derived: sum of 2 quarters · filed 2024-05-09 | $1.58M derived: sum of 3 quarters · filed 2024-05-09 | $1.71M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $240.00K derived: sum of 2 quarters · filed 2024-03-28 | $369.00K derived: sum of 3 quarters · filed 2024-03-28 | $373.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $123.00K 10-Q · filed 2023-11-01 | $252.00K derived: sum of 2 quarters · filed 2023-11-01 | $256.00K 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $129.00K 10-Q · filed 2023-08-08 | $133.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $4.00K 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |